In conclusion, our investigation has identified a targetable miR-181a/PPFIA1/PARP1/NF-κB-P65/KIT regulatory axis that modulates KIT expression in CML. The gene discussed is PARP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.